Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to $270.8 million.

  • Macrogenics' Liabilities and Shareholders Equity rose 237.1% to $270.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 98.12%. This contributed to the annual value of $261.7 million for FY2024, which is 1231.93% down from last year.
  • Per Macrogenics' latest filing, its Liabilities and Shareholders Equity stood at $270.8 million for Q3 2025, which was up 237.1% from $245.4 million recorded in Q2 2025.
  • Macrogenics' 5-year Liabilities and Shareholders Equity high stood at $435.4 million for Q1 2021, and its period low was $195.3 million during Q3 2022.
  • Over the past 5 years, Macrogenics' median Liabilities and Shareholders Equity value was $271.4 million (recorded in 2022), while the average stood at $292.5 million.
  • Per our database at Business Quant, Macrogenics' Liabilities and Shareholders Equity tumbled by 5018.69% in 2022 and then skyrocketed by 7403.49% in 2023.
  • Over the past 5 years, Macrogenics' Liabilities and Shareholders Equity (Quarter) stood at $335.2 million in 2021, then decreased by 16.34% to $280.5 million in 2022, then grew by 6.4% to $298.4 million in 2023, then fell by 12.32% to $261.7 million in 2024, then increased by 3.48% to $270.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $270.8 million in Q3 2025, compared to $245.4 million in Q2 2025 and $224.6 million in Q1 2025.